We propose that simultaneously blocking estrogen/ERα‐mediated gene activation by ERα antagonist and activation of type I IFNs and ISGs expression by KDM5C inhibitor might be an effective way to suppress ERα‐positive breast cancer cell and tumor growth. This evidence concerns the gene ESR1 and breast carcinoma.